Protocol Ledger

NCT07057791 · Phase II · RECRUITING

Phase II Study of Platinum/Etoposide Plus Ivonescimab for Extensive-Stage Small Cell Lung Cancer

Interventional Phase II clinical trial protocol NCT07057791 sponsored by PrECOG in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2026-03-30 Enrollment: 60 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT07057791
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)60 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT07057791
Protocol FieldVerified Registry Value
NCT IdentifierNCT07057791
Consolidated Lead SponsorPrECOG
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment60 participants (ESTIMATED)
Registered Start Date2026-03-30
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT07057791
Hospital Research SiteLocationSite Profile
University of MiamiMiami, FLOpen Hospital Dossier ->
Northwestern Memorial and Lurie Cancer CenterChicago, ILOpen Hospital Dossier ->
University of MarylandBaltimore, MDOpen Hospital Dossier ->
Morristown Medical CenterMorristown, NJOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI